ClinicaliQ Trial Snapshot
- New bioMarkers tO straTIfy cOlorectal caNcer Referrals — Recruiting • Oncology • NCT07035691.
- What is being tested: A blood test measuring circulating progastrin (hPG80) and transposable elements (TEs) to predict colorectal cancer or polyps in adults referred for urgent colorectal assessment via the 2-week wait pathway or direct access endoscopy.
- Patient eligibility: Adult patients with symptoms suggestive of colorectal pathology referred through the 2-week wait (2WW) cancer referral pathway or straight-to-test endoscopy services in UK primary care.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this observational study is to evaluate if a blood test for circulating progastrin (hPG80) and transposable elements (TEs) can accurately predict colorectal cancer (CRC) or polyps in adult patients referred to the 2-week wait (2WW) or Straight to Test (STT) pathways for suspected lower gastrointestinal cancer. The main questions it aims to answer are: Can plasma hPG80 levels accurately predict a diagnosis of CRC or polyps in patients undergoing standard 2WW investigations? Can transposable elements (TEs) in the plasma serve as predictive biomarkers for CRC diagnosis in…
Eligibility Snapshot
- : * Adult, lower GI 2WW and or Straight to Test (STT) referral patients with suspected lower GI cancer. * Male and Female patients aged >18 years. * 2WW referral patients with no history of inflammatory bowel disease. * Performance status (ECOG 0-2; and 3 pending clinical assessment of fitness). * Patients with capacity to consent to the study.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.